Review: MDMX plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies

Patients with acute myeloid leukemia (AML) have a poor prognosis. The accumulation of genetic and nongenetic alterations in hematopoietic stem/progenitor cells (HSPCs) results in AML, and a growing body of evidence have provided ideas for leukemia prevention and interventions of preleukemic conditions [1 –4]. Approximately 10% of healthy adults aged over 65 have leukemia-related mutations in hematopoietic cells, a condition called clonal hematopoiesis (CH) [5–7]. Leukemic transformation from this “preleukemic” status occurs in some high-risk patients who harbor multiple mutations in specific genes (e.g., splicing factors, ASXL1) and higher variant allele frequency of mutated genes [8–10].
Source: Experimental Hematology - Category: Hematology Authors: Tags: Review Source Type: research